Cure51 raises 15 million euros to unravel the secrets of 'cancer miracles'

Cure51 raises 15 million euros to unravel the secrets of ‘cancer miracles’

When their diagnosis was announced, they were given no more than a few months of life expectancy. And yet, against all odds, they survived, defying all the doctors’ predictions. These “cancer miracles,” which have escaped tumors considered incurable, are not numerous – barely a few tens of thousands around the world. But they could, unknowingly, contain valuable information to advance research.

This is the challenge taken up by Cure51, a young Parisian startup, which on Wednesday, March 20, announced a fundraising of 15 million euros from several investors, including the European champion of healthcare venture capital, Sofinnova, or the businessman Xavier Niel (individual shareholder by World) and Olivier Pomel, CEO of Datadog.

It was launched in 2021 by two experienced entrepreneurs, Nicolas Wolikow, formerly of the pharmaceutical laboratory Ipsen and founder of the teleconsultation platform Qare, and Simon Istolainen, co-founder of My Major Company. This techbio (the companies that apply technological innovations in the field of biology) with 21 employees, which also counts four internationally renowned oncology centers among its shareholders, namely the Gustave-Roussy Institute in Paris and the Center Léon-Bérard in Lyon, has aims to build the largest global database of exceptional cancer survivors. Objective: By analyzing this biological information, to decipher the survival mechanisms of these atypical patients in order to find new treatments.

Anonymized data

For two years, the company has been working to identify these wonders in the four corners of the world, currently focusing on three particularly aggressive cancers: pancreatic cancer, glioblastoma (a brain cancer) and small cell lung cancer. Thanks to partnerships with more than fifty hospitals in thirty-six countries, this involves anonymized data (biopsies, blood tests, imaging, tumor samples, etc.) from more than 1,000 patients, supplemented with questionnaires about their lifestyle habits (diet, mental health, sleep, etc.) that will be collected, cleaned and then consolidated over the coming months to integrate the Cure51 database. This geographical diversity is a wealth. This will not only contribute to the integration of hospitals that are often excluded due to a lack of research resources, but will also strengthen our approach. Differences found in a North American population as well as in East Africa or Asia will have greater scientific value. »specifies Simon Istolainen.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *